Alzheimer disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  The role of the default mode network in representing and remembering mental states

  Boston College· Chestnut Hill, United States· US$35,733 awarded in fiscal year 2026· until Oct 2028

• U.S. Department of Veterans Affairs · I01

  SleepSMART for Veterans with Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• U.S. Department of Veterans Affairs · IK2

  Cognitive Risk Profiles Among Aging Veterans: Harnessing Big Data for Precision Medicine

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• NIH NIA · R03

  Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples

  Massachusetts General Hospital· Boston, United States· US$329,220 awarded in fiscal year 2026· until Sept 2028

• NIH NIA · R01

  Enhanced Mapping of Alzheimer's Disease Risk Loci Using Multimodal RNAseq Data

  Emory University· Atlanta, United States· US$653,912 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Sweden· EU contribution €236,340· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Germany· EU contribution €202,125· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €252,729· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spain· EU contribution €209,915· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Switzerland· EU contribution €1,898,233· until Apr 2032

  The disease is named only in the funder's project summary, not in the title.

10 of 5,135 running projects, newest first. Listed amounts together: US$4.3bn + €321.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Single-cell machine learning uncovers genetically anchored, cell-type specific programs of Alzheimer's disease.

  Nat Commun, Nov 2026

• In Silico Assessment of SYNGAP1 Missense Variant Pathogenicity.

  Hum Mutat, Nov 2026

• Brain Region-Specific Peptide and Proteomic Signatures Inform Alzheimer's Disease Biomarker Panels.

  J Proteome Res, Nov 2026

• Super-Cross-Reactive Recognition Enables Preclinical Diagnosis of Alzheimer's Disease.

  J Am Chem Soc, Oct 2026

• Explainable machine learning for identifying high-risk Alzheimer's disease and key health characteristics among community-dwelling adults.

  Front Public Health, Oct 2026

• Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer's disease.

  Transl Psychiatry, Oct 2026

• Advances in artificial intelligence-driven MRI research in Alzheimer's disease.

  Front Neurol, Oct 2026

• A model of brain function to predict tau across Alzheimer's disease and related disorders.

  Nat Commun, Oct 2026

  Clifford R Jack

• The application progress of artificial intelligence in the diagnosis of Alzheimer's disease.

  Front Neurol, Oct 2026

• EEG-based brain effective and functional connectivity predict PET-defined amyloid positivity in cognitively normal individuals.

  Alzheimers Dement, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.